Cargando…

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

BACKGROUND: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, VeriStrat was evaluated a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C, Smit, E F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505013/ https://www.ncbi.nlm.nih.gov/pubmed/23079575 http://dx.doi.org/10.1038/bjc.2012.470

Ejemplares similares

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients
por: Fidler, Mary Jo, et al.
Publicado: (2018)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)

The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy()
por: Lee, Siow Ming, et al.
Publicado: (2019)

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
por: Cardin, Dana B, et al.
Publicado: (2014)

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
por: Lind, Joline S. W., et al.
Publicado: (2010)

CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
por: Vroling, L, et al.
Publicado: (2010)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Response to Hulliard, Le Strat, Dubertre, et al.
por: Carreira, Helena, et al.
Publicado: (2019)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Xenon as a transdermal enhancer for niacinamide in Strat-M™ membranes
por: Petrov, Evgeny, et al.
Publicado: (2021)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach
por: Grigorieva, Julia, et al.
Publicado: (2020)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Association Between Motor and Cognitive Performances in Elderly With Atrial Fibrillation: Strat-AF Study
por: Salvadori, Emilia, et al.
Publicado: (2020)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Explaining multivariate molecular diagnostic tests via Shapley values
por: Roder, Joanna, et al.
Publicado: (2021)

Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results
por: Ramella, Sara, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
por: Chen, M-C, et al.
Publicado: (2013)

Evaluation of Formulation Parameters on Permeation of Ibuprofen from Topical Formulations Using Strat-M(®) Membrane
por: Bolla, Pradeep Kumar, et al.
Publicado: (2020)

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
por: Grossi, F, et al.
Publicado: (2017)

Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC
por: Keek, Simon A., et al.
Publicado: (2022)

A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC
por: Krentz Gober, Madeline, et al.
Publicado: (2017)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country
por: Mugabe, Marcellin, et al.
Publicado: (2021)

Hydrogel Formulations for Topical Insulin Application: Preparation, Characterization and In Vitro Permeation across the Strat-M(®) Membrane
por: Ostróżka-Cieślik, Aneta, et al.
Publicado: (2023)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

A proposal for score assignment to characterize biological processes from mass spectral analysis of serum
por: Roder, Joanna, et al.
Publicado: (2020)

Usefulness of Artificial Membrane, Strat-M(®), in the Assessment of Drug Permeation from Complex Vehicles in Finite Dose Conditions
por: Arce, Florencio Jr, et al.
Publicado: (2020)

A Mathematical Approach Using Strat-M(®) to Predict the Percutaneous Absorption of Chemicals under Finite Dose Conditions
por: Kunita, Ryoki, et al.
Publicado: (2022)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
por: Zou, Bin, et al.
Publicado: (2018)

Rationale, design, and baseline characteristics of Chinese registry in early detection and risk stratification of coronary plaques (C-STRAT) study
por: Yang, Jun-Jie, et al.
Publicado: (2021)

XPERT(®) breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results)
por: Borges, Pamela C C, et al.
Publicado: (2023)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
por: Zhou, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sbjts9nkeenbqr0gpgkh8ana19